These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 29177081)

  • 41. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).
    Burmester GR; Feist E; Kellner H; Braun J; Iking-Konert C; Rubbert-Roth A
    Ann Rheum Dis; 2011 May; 70(5):755-9. PubMed ID: 21187298
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?
    Mian AN; Ibrahim F; Scott DL; Galloway J;
    Arthritis Res Ther; 2016 Jun; 18(1):142. PubMed ID: 27312203
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Disease-modifying treatment for inflammatory rheumatism in sub-Saharan Africa: outcome at 6 months of 205 Senegalese patients with rheumatoid arthritis].
    Ndongo S; Pouye A; Lekpa FK; Bihéhé DM; Tiendrebeogo J; Ndao AC; Ka MM; Moreira Diop T
    Med Sante Trop; 2012; 22(4):385-9. PubMed ID: 23352953
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is current smoking status and its relationship to anti-cyclic citrullinated peptide antibodies a predictor of worse response to biological therapies in rheumatoid arthritis patients?
    Torrente-Segarra V; Bergstra SA; Solomon-Escoto K; Da Silva J; Veale DJ; Al-Emadi S; Huizinga T
    Scand J Rheumatol; 2018 Sep; 47(5):360-363. PubMed ID: 29683356
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
    Valleala H; Korpela M; Möttönen T; Hienonen-Kempas T; Kauppi M; Hannonen P; Leirisalo-Repo M
    Scand J Rheumatol; 2009; 38(5):323-7. PubMed ID: 19585384
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Th17 and CD24
    Salomon S; Guignant C; Morel P; Flahaut G; Brault C; Gourguechon C; Fardellone P; Marolleau JP; Gubler B; Goëb V
    Arthritis Res Ther; 2017 Feb; 19(1):33. PubMed ID: 28183330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    de Punder YM; Fransen J; Kievit W; Houtman PM; Visser H; van de Laar MA; van Riel PL
    Rheumatology (Oxford); 2012 Sep; 51(9):1610-7. PubMed ID: 22539487
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration.
    Chatzidionysiou K; Lukina G; Gabay C; Hetland ML; Hauge EM; Pavelka K; Nordström D; Canhão H; Tomsic M; Rotar Z; Lie E; Kvien TK; van Vollenhoven RF; Saevarsdottir S
    Scand J Rheumatol; 2019 Jan; 48(1):17-23. PubMed ID: 30260261
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.
    Schiff M; Keiserman M; Codding C; Songcharoen S; Berman A; Nayiager S; Saldate C; Li T; Aranda R; Becker JC; Lin C; Cornet PL; Dougados M
    Ann Rheum Dis; 2008 Aug; 67(8):1096-103. PubMed ID: 18055472
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
    Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study.
    Alten R; Nüßlein HG; Mariette X; Galeazzi M; Lorenz HM; Cantagrel A; Chartier M; Poncet C; Rauch C; Le Bars M
    RMD Open; 2017; 3(1):e000345. PubMed ID: 28243468
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
    Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
    Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Toward Defining Primary and Secondary Nonresponse in Rheumatoid Arthritis Patients Treated with Anti-TNF: Results from the BioTRAC and OBRI Registries.
    Keystone EC; Rampakakis E; Movahedi M; Cesta A; Stutz M; Sampalis JS; Nantel F; Maslova K; Bombardier C
    J Rheumatol; 2020 Apr; 47(4):510-517. PubMed ID: 31263067
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis.
    Guyot P; Taylor P; Christensen R; Pericleous L; Poncet C; Lebmeier M; Drost P; Bergman G
    Arthritis Res Ther; 2011; 13(6):R204. PubMed ID: 22151924
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis -- results from the DANBIO registry.
    Jawaheer D; Olsen J; Hetland ML
    J Rheumatol; 2012 Jan; 39(1):46-53. PubMed ID: 22089458
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
    Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
    J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice.
    Pers YM; Fortunet C; Constant E; Lambert J; Godfrin-Valnet M; De Jong A; Mercier G; Pallot Prades B; Wendling D; Gaudin P; Jorgensen C; Marotte H; Maillefert JF
    Rheumatology (Oxford); 2014 Jan; 53(1):76-84. PubMed ID: 24056521
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs in rheumatoid arthritis: results of the GO-MORE study in Spain.
    Alonso A; González CM; Ballina J; García Vivar ML; Gómez-Reino JJ; Marenco JL; Fernández-Nebro A; Ordás C; Cea-Calvo L; Arteaga MJ; Sanmartí R
    Reumatol Clin; 2015; 11(3):144-50. PubMed ID: 25022442
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
    Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
    Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.